Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design DOI Creative Commons
Yan-Ruide Li, Christopher Ochoa, Yichen Zhu

et al.

iScience, Journal Year: 2023, Volume and Issue: 26(10), P. 107952 - 107952

Published: Sept. 19, 2023

Ovarian cancer (OC) is highly lethal due to late detection and frequent recurrence. Initial treatments, comprising surgery chemotherapy, lead disease remission but are invariably associated with subsequent relapse. The identification of novel therapies an improved understanding the molecular cellular characteristics OC urgently needed. Here, we conducted a comprehensive analysis primary tumor cells their microenvironment from 16 chemonaive 10 recurrent patient samples. Profiling biomarkers allowed for potential targets developing immunotherapies, while profiling yielded insights into its composition property changes between Notably, identified CD1d as biomarker demonstrated targeting by invariant natural killer T (iNKT) cells. Overall, our study presents immuno-profiling during progression, guiding development immunotherapies treatment, especially disease.

Language: Английский

Heterogeneity and treatment landscape of ovarian carcinoma DOI
Ana Veneziani, Eduardo González-Ochoa,

Husam Alqaisi

et al.

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(12), P. 820 - 842

Published: Oct. 2, 2023

Language: Английский

Citations

69
Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities DOI Creative Commons
Chunyan Liu, Qinan Yin,

Zhaoying Wu

et al.

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 895 - 909

Published: Jan. 1, 2025

Ovarian cancer (OC) remains one of the most lethal gynecological malignancies, largely due to its late-stage diagnosis and high recurrence rates. Chronic inflammation is a critical driver OC progression, contributing immune evasion, tumor growth, metastasis. Inflammatory cytokines, including IL-6, TNF-α, IL-8, as well key signaling pathways such nuclear factor kappa B (NF-kB) signal transducer activator transcription 3 (STAT3), are upregulated in OC, promoting tumor-promoting environment. The microenvironment (TME) characterized by cells like tumor-associated macrophages (TAMs) regulatory T (Tregs), which suppress anti-tumor responses, facilitating evasion. Furthermore, utilize checkpoint pathways, PD-1/PD-L1, inhibit cytotoxic cell activity. Targeting these inflammatory evasion mechanisms offers promising therapeutic strategies. COX-2 inhibitors, Janus kinase/signal (JAK/STAT) pathway blockers, NF-kB inhibitors have shown potential preclinical studies, while targeting PD-1/PD-L1 CTLA-4 been explored with mixed results OC. Additionally, emerging research on microbiome inflammation-related biomarkers, microRNAs (miRNAs) exosomes, points new opportunities for early detection precision medicine. Future approaches treatment must focus personalized strategies that target TME, integrating anti-inflammatory therapies immunotherapy enhance patient outcomes. Continued into interplay between essential developing effective, long-lasting treatments.

Language: Английский

Citations

3
Macrophage-derived lncRNAs in cancer: regulators of tumor progression and therapeutic targets DOI
Muath Suliman, Raed Obaid Saleh,

M Chandra

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(4)

Published: March 6, 2025

Language: Английский

Citations

2
Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs DOI Creative Commons
Shengwen Shao, Huilai Miao, Wenxue Ma

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 14, 2023

Tumor-associated macrophages (TAMs) are integral to the tumor microenvironment (TME), influencing cancer progression significantly. Attracted by cell signals, TAMs exhibit unparalleled adaptability, aligning with dynamic milieu. Their roles span from promoting growth and angiogenesis modulating metastasis. While substantial research has explored fundamentals of TAMs, comprehending their adaptive behavior, leveraging it for novel treatments remains challenging. This review delves into TAM polarization, metabolic shifts, complex orchestration cytokines chemokines determining functions. We highlight complexities TAM-targeted focusing on adaptability potential variability in therapeutic outcomes. Moreover, we discuss synergy integrating TAM-focused strategies established treatments, such as chemotherapy, immunotherapy. Emphasis is laid pioneering methods like reprogramming immunotherapy adoption single-cell technologies precision intervention. synthesis seeks shed light TAMs’ multifaceted cancer, pinpointing prospective pathways transformative enhancing modalities oncology.

Language: Английский

Citations

30
The role of macrophages in the tumor microenvironment and tumor metabolism DOI
Pritam Sadhukhan, Tanguy Y. Seiwert

Seminars in Immunopathology, Journal Year: 2023, Volume and Issue: 45(2), P. 187 - 201

Published: March 1, 2023

Language: Английский

Citations

29
The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities DOI Creative Commons
Bianca Garlisi,

Sylvia Lauks,

Caroline Aitken

et al.

Current Oncology, Journal Year: 2024, Volume and Issue: 31(7), P. 3826 - 3844

Published: July 1, 2024

The tumor microenvironment (TME) in ovarian cancer (OC) has much greater complexity than previously understood. In response to aggressive pro-angiogenic stimulus, blood vessels form rapidly and are dysfunctional, resulting poor perfusion, tissue hypoxia, leakiness, which leads increased interstitial fluid pressure (IFP). Decreased perfusion high IFP significantly inhibit the uptake of therapies into tumor. Within TME, there numerous inhibitor cells, such as myeloid-derived suppressor cells (MDSCs), association macrophages (TAMs), regulatory T (Tregs), cancer-associated fibroblasts (CAFs) that secrete numbers immunosuppressive cytokines. This environment is thought contribute lack success immunotherapies immune checkpoint (ICI) treatment. review discusses components TME OC, how these characteristics impede therapeutic efficacy, some strategies alleviate this inhibition.

Language: Английский

Citations

17
Exosomal long non-coding RNAs in cancer: Interplay, modulation, and therapeutic avenues DOI Creative Commons
Rahaba Marima, Afra Basera, Thabiso Victor Miya

et al.

Non-coding RNA Research, Journal Year: 2024, Volume and Issue: 9(3), P. 887 - 900

Published: April 4, 2024

In the intricate field of cancer biology, researchers are increasingly intrigued by emerging role exosomal long non-coding RNAs (lncRNAs) due to their multifaceted interactions, complex modulation mechanisms, and potential therapeutic applications. These lncRNAs, carried within extracellular vesicles, play a vital partin tumorigenesis disease progression facilitating communication networks between tumor cells local microenvironment, making them an ideal candidates for use in liquid biopsy approach. However, lncRNAs remain understudied area, especially biology. Therefore this review aims comprehensively explore dynamic interplay various cellular components, including interactions with tumor-stroma, immune modulation, drug resistance mechanisms. Understanding regulatory functions these processes can potentially unveil novel diagnostic markers targets cancer. Additionally, emergence RNA-based therapeutics presents exciting opportunities targeting offering innovative strategies combat improve treatment outcomes. Thus, provides insights into current understanding highlighting crucial roles, evolving landscape interventions. Furthermore, we have also discussed advantage exosomes as carriers development personalized targeted therapy patients.

Language: Английский

Citations

16
Targeting lipid metabolism of macrophages: A new strategy for tumor therapy DOI Creative Commons
Nan Shao,

Hui Qiu,

Jing Liu

et al.

Journal of Advanced Research, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 1, 2024

Lipid metabolism has been implicated in a variety of normal cellular processes and strongly related to the development multiple diseases, including tumor. Tumor-associated macrophage (TAM) emerged as crucial regulator tumorigenesis promising target for tumor treatment.

Language: Английский

Citations

15
Multi‑omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study DOI Creative Commons
Lele Ye,

Chunhao Long,

Binbing Xu

et al.

Molecular Medicine, Journal Year: 2025, Volume and Issue: 31(1)

Published: Jan. 8, 2025

Abstract Background Predictive, preventive, and personalized medicine (PPPM/3PM) is a strategy aimed at improving the prognosis of cancer, programmed cell death (PCD) increasingly recognized as potential target in cancer therapy prognosis. However, PCD-based predictive model for serous ovarian carcinoma (SOC) lacking. In present study, we to establish index (CDI)–based using PCD-related genes. Methods We included 1254 genes from 12 PCD patterns our analysis. Differentially expressed (DEGs) Cancer Genome Atlas (TCGA) Genotype-Tissue Expression (GTEx) were screened. Subsequently, 14 PCD-gene-based CDI model. Genomics, single-cell transcriptomes, bulk spatial clinical information TCGA-OV, GSE26193, GSE63885, GSE140082 collected analyzed verify prediction Results The was an independent prognostic risk factor patients with SOC. Patients SOC high had lower survival rates poorer prognoses than those low CDI. Specific parameters combined nomogram that accurately assessed patient survival. used PCD-genes observe differences between groups. results showed immunosuppression hardly benefited immunotherapy; therefore, trametinib_1372 BMS-754807 may be therapeutic agents these patients. Conclusions CDI-based model, which established genes, predicted tumor microenvironment, immunotherapy response, drug sensitivity Thus this help improve diagnostic efficacy PPPM.

Language: Английский

Citations

1
Enhanced Expression of TRIM46 in Ovarian Cancer Cells Induced by Tumor-Associated Macrophages Promotes Invasion via the Wnt/β-Catenin Pathway DOI Creative Commons
Yiyue Wang, Minjun Choi, Jin Hyung Kim

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(3), P. 214 - 214

Published: Feb. 2, 2025

Metastasis presents significant challenges in ovarian cancer treatment. Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) facilitate metastasis through epithelial-mesenchymal transition, yet molecular underlying mechanisms are not fully understood. Here, we identified that tripartite motif-containing 46 (TRIM46) is significantly upregulated cells treated with a conditioned medium derived from stimulated by (OC-MQs). Furthermore, TRIM46 was highly expressed late-stage patients and associated poor prognosis. Silencing of suppressed cell invasion OC-MQ mesenchymal marker expression without affecting viability. Gene set enrichment analysis showed Wnt/β-catenin pathway enriched high-TRIM46 group. Importantly, inhibition TRIM46-mediated β-catenin nuclear translocation reversed CHIR99021, activator. Additionally, C-X-C motif chemokine ligand 8 (CXCL8) as being peritoneal MQs ascites positively correlated receptor 1/2 (CXCR1/2) cells. Notably, pre-treatment reparixin, CXCR1/2 inhibitor, blocked OC-MQ-induced invasion. These results suggest CXCL8 TAMs promotes human via upregulating TRIM46.

Language: Английский

Citations

1